dalpiciclib isethionate tablets; abiraterone acetate tablets; prednisone tablets + placebo; abiraterone acetate tablets; prednisone tablets
Phase 1Recruiting 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
High-volume, Metastatic, Hormone-sensitive Prostate Cancer (mHSPC)
Conditions
High-volume, Metastatic, Hormone-sensitive Prostate Cancer (mHSPC)
Trial Timeline
Oct 1, 2023 → Dec 1, 2028
NCT ID
NCT06099990About dalpiciclib isethionate tablets; abiraterone acetate tablets; prednisone tablets + placebo; abiraterone acetate tablets; prednisone tablets
dalpiciclib isethionate tablets; abiraterone acetate tablets; prednisone tablets + placebo; abiraterone acetate tablets; prednisone tablets is a phase 1 stage product being developed by Jiangsu Hengrui Medicine for High-volume, Metastatic, Hormone-sensitive Prostate Cancer (mHSPC). The current trial status is recruiting. This product is registered under clinical trial identifier NCT06099990. Target conditions include High-volume, Metastatic, Hormone-sensitive Prostate Cancer (mHSPC).
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06099990 | Phase 1 | Recruiting |